Advertisement
INSM vs TRDA
Which Stock Would AI Choose? Insmed Incorporated (INSM) vs. Entrada Therapeutics, Inc. (TRDA) Stock Comparison
Key Takeaways
- Insmed Incorporated (INSM) operates with approved therapies and a broader commercial presence in respiratory diseases, while Entrada Therapeutics, Inc. (TRDA) remains a clinical-stage biotechnology company focused on intracellular delivery platforms.
- Recent market activity showed Insmed Incorporated (INSM) benefiting from positive 12-month data on its Treprostinil Palmitil Inhalation Powder (TPIP) candidate for pulmonary arterial hypertension (PAH).
- Entrada Therapeutics, Inc. (TRDA) has seen comparatively limited near-term catalysts in recent weeks, with its pipeline centered on early-stage genetic medicines for neuromuscular and retinal conditions.
- Insmed Incorporated (INSM) maintains higher market capitalization and revenue visibility from existing products such as ARIKAYCE, contrasting with Entrada Therapeutics, Inc. (TRDA)'s smaller scale and pre-commercial status.
- Sector exposure for both centers on biotechnology, yet Insmed Incorporated (INSM) demonstrates more diversified development across multiple late-stage assets compared with Entrada Therapeutics, Inc. (TRDA)'s narrower focus.
- Market sentiment in recent weeks has reflected greater visibility around Insmed Incorporated (INSM) clinical updates versus a quieter period for Entrada Therapeutics, Inc. (TRDA).
Introduction
Biotechnology stocks often attract investors seeking exposure to clinical progress and commercial potential in rare and serious diseases. This comparison examines Insmed Incorporated (INSM) and Entrada Therapeutics, Inc. (TRDA), two companies operating in overlapping therapeutic areas but at different stages of development. The analysis targets traders and investors evaluating relative performance, pipeline momentum, and positioning within the biotechnology sector amid evolving market conditions. It highlights contrasts in business maturity, recent activity, and risk profiles to support informed assessment of these equities.
INSM Overview and Recent Performance
Insmed Incorporated (INSM) is a biopharmaceutical company developing and commercializing therapies for serious and rare diseases, primarily in respiratory and infectious conditions. Its approved products include ARIKAYCE for nontuberculous mycobacterial lung disease and BRINSUPRI for bronchiectasis. In recent weeks, positive 12-month data from the open-label extension study of Treprostinil Palmitil Inhalation Powder (TPIP) in patients with pulmonary arterial hypertension (PAH) contributed to sentiment. The company also announced plans to host its second-quarter 2026 financial results conference call in early August. These updates occurred against a backdrop of ongoing commercialization efforts and pipeline advancement, supporting relative stability in stock behavior during the period.
TRDA Overview and Recent Performance
Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company developing a new class of medicines that engage intracellular targets previously considered inaccessible. Its Endosomal Escape Vehicle platform supports candidates for neuromuscular and inherited retinal diseases. In recent weeks, the company maintained a lower public profile with fewer announced clinical or corporate developments compared with peers. Stock performance reflected this quieter period, with limited new catalysts emerging to influence broader market sentiment. The firm continues to advance its preclinical and early clinical portfolio while operating from a smaller market capitalization base.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that analyze and trade thousands of different tickers across various market conditions. Only the strongest performers suited to prevailing environments receive placement in the curated Trending AI Robots section. These bots encompass diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, allowing users to review statistical ranges such as win rates, profit factors, and drawdown profiles. The selection emphasizes transparency in backtested and live results. For further details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
Insmed Incorporated (INSM) maintains a more mature business model with multiple approved products generating revenue, whereas Entrada Therapeutics, Inc. (TRDA) remains pre-commercial and reliant on platform validation through clinical milestones. Growth drivers for Insmed Incorporated (INSM) include expanding indications for existing assets and near-term data readouts, while Entrada Therapeutics, Inc. (TRDA) centers on its proprietary intracellular delivery technology with earlier-stage candidates. Recent momentum favored Insmed Incorporated (INSM) following clinical updates, contrasting with Entrada Therapeutics, Inc. (TRDA)'s steadier but less event-driven trajectory. Risk factors differ in scale: Insmed Incorporated (INSM) faces commercialization and competitive pressures, while Entrada Therapeutics, Inc. (TRDA) contends with typical early-stage biotechnology execution and funding risks. Both companies operate within the biotechnology sector, yet Insmed Incorporated (INSM) offers broader pipeline diversification and established market presence.
Tickeron AI Verdict
Based on observable factors such as recent clinical catalysts, trend consistency in development updates, and relative positioning with approved revenue streams, Tickeron’s AI would currently assign a higher probability of favorable positioning to Insmed Incorporated (INSM) over Entrada Therapeutics, Inc. (TRDA). This assessment reflects greater near-term visibility for Insmed Incorporated (INSM) amid ongoing pipeline progress, though outcomes remain subject to broader market dynamics and execution risks for both equities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and TRDA is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green whileTRDA’s FA Score has 0 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- TRDA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 5 TA indicator(s) are bullish while TRDA’s TA Score has 5 bullish TA indicator(s).
- INSM’s TA Score: 5 bullish, 5 bearish.
- TRDA’s TA Score: 5 bullish, 5 bearish.
Price Growth
INSM (@Biotechnology) experienced а -1.29% price change this week, while TRDA (@Biotechnology) price change was -15.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.
Reported Earning Dates
INSM is expected to report earnings on Aug 06, 2026.
TRDA is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (-4.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INSM | TRDA | INSM / TRDA | |
| Capitalization | 23.2B | 227M | 10,220% |
| EBITDA | -1.08B | -174.46M | 621% |
| Gain YTD | -38.566 | -43.093 | 89% |
| P/E Ratio | N/A | 10.26 | - |
| Revenue | 820M | 5.74M | 14,291% |
| Total Cash | 1.22B | 76.4M | 1,602% |
| Total Debt | 580M | 49.8M | 1,165% |
INSM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 63 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| INSM | TRDA | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 66% | 3 days ago 79% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 87% |
| MACD ODDS (%) | 3 days ago 70% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 85% |
| TrendMonth ODDS (%) | 3 days ago 74% | 3 days ago 86% |
| Advances ODDS (%) | 18 days ago 71% | 12 days ago 86% |
| Declines ODDS (%) | 11 days ago 73% | 3 days ago 85% |
| BollingerBands ODDS (%) | 3 days ago 73% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 73% | 3 days ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| JMVRX | 35.77 | 0.35 | +0.99% |
| JPMorgan Mid Cap Value R5 | |||
| RMYYX | 10.56 | 0.03 | +0.28% |
| Russell Inv Multi-Strategy Income Y | |||
| FLRAX | 46.64 | 0.08 | +0.17% |
| Nuveen Large Cap Select A | |||
| FIDJX | 18.02 | -0.02 | -0.11% |
| Fidelity SAI Sustainable Sector Fund | |||
| FTTEX | 16.61 | -0.08 | -0.48% |
| Fidelity Advisor Total Intl Equity M | |||
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -0.46% | ||
| CNTN - INSM | 74% Closely correlated | -5.83% | ||
| TRDA - INSM | 51% Loosely correlated | -3.31% | ||
| ENGN - INSM | 48% Loosely correlated | -3.70% | ||
| AXON - INSM | 40% Loosely correlated | +2.12% | ||
| ARRY - INSM | 40% Loosely correlated | -5.42% | ||
More | ||||
TRDA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TRDA has been closely correlated with ENGN. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRDA jumps, then ENGN could also see price increases.
| Ticker / NAME | Correlation To TRDA | 1D Price Change % | ||
|---|---|---|---|---|
| TRDA | 100% | -3.31% | ||
| ENGN - TRDA | 78% Closely correlated | -3.70% | ||
| INSM - TRDA | 51% Loosely correlated | -0.46% | ||
| KRRO - TRDA | 42% Loosely correlated | -7.72% | ||
| CELC - TRDA | 42% Loosely correlated | -6.47% | ||
| PCVX - TRDA | 40% Loosely correlated | -1.76% | ||
More | ||||